NightHawk Biosciences, Inc.(NYSE Amex Equities : NHWK)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 0.58% | 177.12 | 0.7% | $1156.59m | |
| LLY | Eli Lilly & Co. | 0.96% | 372.06 | 1.1% | $1068.92m | |
| MRK | Merck & Co., Inc. | 1.06% | 110.08 | 0.7% | $1002.54m | |
| PFE | Pfizer Inc. | 1.09% | 50.25 | 0.9% | $935.84m | |
| ABBV | AbbVie, Inc. | 0.98% | 165.32 | 1.9% | $895.13m | |
| BMY | Bristol-Myers Squibb Co. | 0.01% | 79.93 | 1.1% | $742.00m | |
| AZN | AstraZeneca Plc | 0.42% | 68.85 | 1.0% | $354.37m | |
| HZNP | Horizon Therapeutics Plc | -0.57% | 96.30 | 5.4% | $286.44m | |
| GSK | GSK Plc | -2.74% | 36.88 | 0.3% | $251.05m | |
| IDXX | IDEXX Laboratories, Inc. | 1.13% | 420.10 | 3.9% | $191.38m | |
| NVS | Novartis AG | 1.09% | 91.73 | 0.2% | $188.48m | |
| CTLT | Catalent, Inc. | -2.05% | 47.23 | 1.9% | $170.45m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 5.32% | 231.33 | 8.0% | $168.15m | |
| NVO | Novo Nordisk A/S | -0.42% | 125.26 | 0.1% | $152.07m | |
| SNY | Sanofi | -1.26% | 47.94 | 0.2% | $138.09m |
Company Profile
NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.